NCT05906992: An ongoing trial by Celltrion
This trial is ongoing. It must report results 2 years, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05906992 |
|---|---|
| Title | A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 1/3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 11, 2024 |
| Completion date | Feb. 28, 2027 |
| Required reporting date | Feb. 28, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |